Sophiris Bio, Inc. SPHS-Financial and Strategic SWOT Analysis Review

Sophiris Bio, Inc. SPHS-Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH82545FSA
  • |
  • Pages: 47
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Sophiris Bio, Inc. (SPHS)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sophiris Bio, Inc. (Sophiris) is a clinical stage bio-pharmaceutical company, which focuses on developing products for the treatment of urological diseases. Sophiris lead drug candidate, PRX302 is under late stage development for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate. It is a modified recombinant protein that is delivered through ultrasound-guided injection directly into the prostate. This drug is engineered to be active only in prostate tissue. The company's PRX302 is also being developed for the treatment of low to intermediate risk prostate cancer. Sophiris is headquartered in La Jolla, California, the US.

Sophiris Bio, Inc. Key Recent Developments

May 16, 2016: Sophiris Bio Reports First Quarter 2016 Financial Results and Key Business Highlights

Mar 23, 2016: Sophiris Bio Reports Fourth Quarter and Full Year 2015 Financial Results and Key Business Highlights

Nov 16, 2015: Sophiris Bio Reports Third Quarter Financial Results and Business Highlights

Aug 13, 2015: Sophiris Bio Reports Second Quarter Financial Results

May 13, 2015: Sophiris Bio Reports First Quarter 2015 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Section 1-About the Company 6

Sophiris Bio, Inc.-Key Facts 6

Sophiris Bio, Inc.-Key Employees 7

Sophiris Bio, Inc.-Key Employee Biographies 8

Sophiris Bio, Inc.-Major Products and Services 9

Sophiris Bio, Inc.-Pharmaceutical Pipeline Products Data 10

Sophiris Bio, Inc., Pipeline Products by Therapy Area 10

Sophiris Bio, Inc., Pipeline Products by Development Phase 11

Sophiris Bio, Inc.-History 12

Sophiris Bio, Inc.-Company Statement 14

Sophiris Bio, Inc.-Locations And Subsidiaries 17

Head Office 17

Other Locations & Subsidiaries 17

Section 2-Company Analysis 18

Sophiris Bio, Inc.-Business Description 18

Sophiris Bio, Inc.-Corporate Strategy 19

Sophiris Bio, Inc.-SWOT Analysis 20

SWOT Analysis-Overview 20

Sophiris Bio, Inc.-Strengths 20

Strength-Strong Intellectual Property Portfolio 20

Strength-Focused Research and Development Activities 20

Strength-Lead Product: PRX302 20

Sophiris Bio, Inc.-Weaknesses 21

Weakness-History of Losses 21

Weakness-Working Capital Concerns 21

Sophiris Bio, Inc.-Opportunities 22

Opportunity-Rising Healthcare Expenditure in the US 22

Opportunity-Market Potential: Prostate Cancer 22

Opportunity-Changing Demographics 22

Sophiris Bio, Inc.-Threats 23

Threat-Regulatory Oversight 23

Threat-Intense Competition 23

Threat-Reliance on Third Parties 23

Sophiris Bio, Inc.-Key Competitors 24

Section 3-Company Financial Ratios 25

Financial Ratios-Capital Market Ratios 25

Financial Ratios-Annual Ratios 26

Performance Chart 27

Financial Performance 27

Financial Ratios-Interim Ratios 28

Financial Ratios-Ratio Charts 29

Section 4-Company's Lifesciences Financial Deals and Alliances 30

Sophiris Bio, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 30

Sophiris Bio, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 31

Sophiris Bio, Inc., Recent Deals Summary 32

Section 5-Company's Recent Developments 33

May 16, 2016: Sophiris Bio Reports First Quarter 2016 Financial Results and Key Business Highlights 33

Mar 23, 2016: Sophiris Bio Reports Fourth Quarter and Full Year 2015 Financial Results and Key Business Highlights 35

Nov 16, 2015: Sophiris Bio Reports Third Quarter Financial Results and Business Highlights 37

Aug 13, 2015: Sophiris Bio Reports Second Quarter Financial Results 39

May 13, 2015: Sophiris Bio Reports First Quarter 2015 Financial Results 40

Mar 10, 2015: Sophiris Bio Reports Fourth Quarter and Full Year Financial Results 41

Section 6-Appendix 43

Methodology 43

Ratio Definitions 43

About GlobalData 47

Contact Us 47

Disclaimer 47

List of Figures

Sophiris Bio, Inc., Pipeline Products by Therapy Area 10

Sophiris Bio, Inc., Pipeline Products by Development Phase 11

Sophiris Bio, Inc., Performance Chart (2011-2015) 27

Sophiris Bio, Inc., Ratio Charts 29

Sophiris Bio, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 30

Sophiris Bio, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 31

List of Tables

Sophiris Bio, Inc., Key Facts 6

Sophiris Bio, Inc., Key Employees 7

Sophiris Bio, Inc., Key Employee Biographies 8

Sophiris Bio, Inc., Major Products and Services 9

Sophiris Bio, Inc., Number of Pipeline Products by Therapy Area 10

Sophiris Bio, Inc., Number of Pipeline Products by Development Stage 11

Sophiris Bio, Inc., Pipeline Products By Therapy Area and Development Phase 11

Sophiris Bio, Inc., History 12

Sophiris Bio, Inc., Subsidiaries 17

Sophiris Bio, Inc., Key Competitors 24

Sophiris Bio, Inc., Ratios based on current share price 25

Sophiris Bio, Inc., Annual Ratios 26

Sophiris Bio, Inc., Interim Ratios 28

Sophiris Bio, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 30

Sophiris Bio, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 31

Sophiris Bio, Inc., Recent Deals Summary 32

Currency Codes 43

Capital Market Ratios 43

Equity Ratios 44

Profitability Ratios 44

Cost Ratios 45

Liquidity Ratios 45

Leverage Ratios 46

Efficiency Ratios 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Lipocine Inc.

Astellas Pharma US, Inc.

Actavis Inc.

Sophiris Bio, Inc., SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license

Single User License
USD 125 INR 8045
Site License
USD 250 INR 16090
Corporate User License
USD 375 INR 24135

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com